Do We Really Need End-To-End Continuous Processing for Biomanufacturing of Monoclonal Antibodies?

Patients around the world, especially in low- or medium-income countries (LMICs), are unable to afford the prohibitively high cost of monoclonal antibodies (mAbs). One promising approach to this issue of accessibility and affordability is intensifyin…

Preview only. Read the full abstract at the source